Penton Base Mutants for Organelle Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for improving cell membrane penetration and intracellular trafficking of therapeutic agents are time-consuming and labor-intensive, relying on rational design and empirical testing of peptides, which may not yield optimal results.
Innovation Solution
A directed evolution approach is used to generate penton base protein mutants with enhanced cell penetration and trafficking functions by selective pressure, creating a library of variants that target specific organelles and deliver therapeutic agents effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rational design and empirical testing of peptides are used to improve cell membrane penetration and intracellular trafficking, then therapeutic agents can be delivered to targeted organelles, but the process becomes time-consuming and labor-intensive
Solution Approach 1:
The patent employs directed evolution to allow the penton base protein to self-optimize its cell penetration and trafficking functions through iterative rounds of mutation and selection. The system automatically generates variants and selects those with improved properties, eliminating the need for time-consuming rational design and empirical testing by human researchers.
Solution Approach 2:
The patent systematically varies amino acid residues at specific positions (111, 333, and other conserved residues) in the penton base protein to generate diverse mutants. By changing these critical parameters and selecting mutants with enhanced trafficking to the nucleus and cytoplasm, the method accelerates the optimization process while maintaining reliable therapeutic delivery.
2Manufacturing precision
If rational design methods are used to create cell penetration peptides, then targeted organelle delivery can be achieved, but the process requires extensive empirical testing and may not yield optimal results
Solution Approach 1:
The patent performs preliminary action by pre-selecting critical amino acid positions (111, 333, and other conserved residues) in the penton base protein that are most likely to influence cell penetration and intracellular trafficking. By focusing mutations on these predetermined positions, the method achieves precise trafficking optimization more efficiently than random empirical testing.
Solution Approach 2:
The patent systematically changes amino acid parameters at specific positions to generate a focused library of mutants. This targeted parameter variation, combined with selection for enhanced nuclear and cytoplasmic trafficking, achieves both manufacturing precision and improved productivity compared to traditional rational design.
3Reliability
If traditional methods are used to improve cell penetration, then some therapeutic delivery can be achieved, but the results are suboptimal compared to directed evolution approaches
Solution Approach 1:
The directed evolution methodology allows the protein to self-optimize through iterative mutation and selection, automatically generating high-efficacy variants without requiring complex rational design procedures. This self-service approach achieves superior delivery effectiveness while maintaining relative simplicity in the manufacturing process.
Solution Approach 2:
The patent applies the directed evolution approach to simultaneously optimize multiple functions of the penton base protein, including cell membrane penetration, endosomal escape, and trafficking to specific organelles (nucleus and cytoplasm). This multi-functional optimization achieves superior overall delivery effectiveness compared to traditional single-function optimization methods.
Data Source
AI summary
The invention relates to methods for isolating traffic-enhancing mutants of drug delivery proteins. In one embodiment, the invention provides a carrier for delivering a therapeutic agent to an organelle, comprising a polypeptide encoded by a mutant penton base gene. In another embodiment, the invention provides a method of enhancing trafficking to a cell by administering a composition comprising a penton base (PB) protein with one or more mutations that enhance cellular entry.